Navigation Links
NuVasive Completes Acquisition of Osteocel Biologics Business

robust growth;

-- Provides opportunity for additional revenue per procedure of $2,000 to $3,000;

-- Complements current Formagraft(R) biologic product line;

-- Allows for participation in all segments of the $1.5 billion U.S. biologics market;

-- Leverages current market adoption of an established biologic used in over 15,000 procedures to date; and

-- Includes rights to acquire next generation cultured version of product.

Alex Lukianov, Chairman and Chief Executive Officer, said, "We are pleased to complete the acquisition of the Osteocel biologics business, which represents a significant milestone in our strategy to expand our product portfolio with synergistic and innovative technologies. For the remainder of 2008, we will continue to sell Osteocel through its prearranged distribution agreements and begin compiling additional data in support of the product. We believe there is substantial opportunity to create an aggressive marketing program to achieve this product's full potential and, combined with our Formagraft product, we look to create a $100 million biologics business over the next several years."

Financial Guidance

NuVasive expects that the Osteocel biologics business will add revenues of $15 million in 2008, based on the contractual terms of existing distribution agreements, and $25 million of revenue in 2009, when Osteocel will be transitioned to NuVasive's exclusive sales force. In 2008, the Company expects Osteocel gross margins of mid 30% based on the existing distribution agreements, and in 2009, expects Osteocel gross margins to approach 60%. The Company expects the transaction to be dilutive to GAAP earnings per share in 2008 because of an in-process R&D charge of approximately $15-$20 million. Excluding this charge, the Company expects the result to be neutral earnings in both 2008 and 2009.

Deal Structure

NuVasive is making a closing payment of $35 million in cash. Osiris wil

SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results
2. NuVasive to Present at William Blair 28th Annual Growth Stock Conference
3. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
4. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
5. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
7. NuVasive to Host Investor Reception on September 11, 2007
8. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
9. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
10. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
11. Accuri Cytometers Completes $13 Million Series C Financing
Post Your Comments:
(Date:4/16/2015)... (PRWEB) April 16, 2015 Proove ... Buzz of BIO Contest for the 2015 ... (BIO), the 2015 BIO International Convention will take place ... Pennsylvania. During the Buzz of BIO contest, industry leaders ... see present at the conference. The community voting period ...
(Date:4/16/2015)... OncoTAb, Inc., a University ... company, announced today the appointment of physician and ... Operating Officer (COO). Cooper brings to OncoTAb more ... diagnostic and biotechnology platforms in the fields of ... career transcends the field of medical and scientific ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
Breaking Biology Technology:Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... PARK, N.C., Jan. 14, 2011 Talecris Biotherapeutics Holdings Corp. ... established a new record date and meeting date for the ... merger agreement under which Grifols (GRF.MC) will acquire TLCR. ... on January 11, 2011 will be entitled to vote at ...
... now open for StemCONN 2011. The full-day ... cell research, will take place Tuesday, March 22, in ... the UConn Health Center (commercial session and tour). ... . StemCONN 2011 will feature a ...
... reversal of tinnitus, a debilitating hearing impairment affecting at ... 40 percent of military veterans, according to an article ... Nature . Researchers Dr. Michael Kilgard and ... Dallas and University-affiliated biotechnology firm MicroTransponder report that stimulation ...
Cached Biology Technology:Nature article focuses on tinnitus treatment 2Nature article focuses on tinnitus treatment 3
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... Ecology drives evolution. In today,s issue of the journal ... growing evidence that the reverse is also true, and ... how environmental change affects species and vice-versa. A ... a Galpagos ground finch, Geospiza fortis. In this species, ...
... available in French . , Montreal, January 28, 2011 ... a rare form of cancer that caused a strange combination of ... his stomach and colon. His medical team was stumped and was ... family: the cause of his disease and the risk for future ...
... University of the Negev (BGU) and the PTT Chemical ... research and development collaboration agreement for commercial development of ... for the production of dihomo gamma-linolenic acid (DGLA- Omega ... Parietochloris incise. The joint research will focus on optimizing ...
Cached Biology News:Cold cases gone hot: Montreal researchers solve decades-old medical mysteries using genetics 2Ben-Gurion U. and PTT Chemical sign R&D agreement to commercialize green algae strain 2
... & visualization software. See ... samples. Combine Sequest and ... confidence. Get more detailed ... your MS/MS experiments.14 day ...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Biology Products: